Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SRSD216 injection
SRSD216 · 1 trial · 1 indication
A summary of TEAE to evaluate the safety and tolerability of SRSD216
| Arm | Type | Description |
|---|---|---|
| SRSD216 injection (Part 1) | EXPERIMENTAL | SRSD216 administered SC. in subjects of Part 1 |
| SRSD216 injection (Part 2) | EXPERIMENTAL | SRSD216 administered SC. in subjects of Part 2 |
| 0.9% Sodium Chloride (Part 1) | EXPERIMENTAL | Placbo administered SC. in subjects of Part 1 |
| 0.9% Sodium Chloride (Part 2) | PLACEBO_COMPARATOR | Placbo administered SC. in subjects of Part 2 |
| Name | Type | Description |
|---|---|---|
| SRSD216 injection | DRUG | Administered SC. |
| Placebo | DRUG | Administered SC. |
Inclusion Criteria: * Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions; * Males or females, of any race; * Body mass index (BMI) between 18.0 and 40.0 kg/m2, inclusive; * Male subjects are not allowed to donate sperm, and female subjects a...
SRSD216 is an investigational small molecule being developed for hyperlipoproteinemia (a), a condition of elevated lipoprotein (a) levels. It is currently in Phase 1 clinical development and has not been approved by any regulatory authority.
SRSD216 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker YCBD. The drug is in Phase 1 clinical development for hyperlipoproteinemia (a).
SRSD216 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 trial is currently recruiting participants with elevated lipoprotein (a) levels.
SRSD216 is being studied in a Phase 1 clinical trial registered as NCT07172646. This randomized, double-blind, placebo-controlled study is recruiting 84 participants in China, including healthy volunteers, to evaluate the drug in patients with elevated lipoprotein (a).
Yes, SRSD216 is also known as SRSD216 injection. Both names refer to the same investigational drug being developed by cbdMD, Inc. for hyperlipoproteinemia (a).